DMEMEDS shared post via Reuters: Eli Lilly drug prolongs survival in large lung cancer trial

(Reuters) - Eli Lilly and Co's cancer drug ramucirumab modestly extended survival in a large, late-stage study of patients with advanced, nonsmall cell lung cancer who had relapsed following initial treatment, according to data presented on Saturday. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/7dzM6c_zGz4/story01.htm

Read More